Genmab | GEN - Cost Of Sales

Stock Price
1,848.50
Daily Change
14.00 0.76%
Monthly
-9.79%
Yearly
14.92%
Q1 Forecast
1,757.86

Genmab reported DKK57M in Cost of Sales for its fiscal quarter ending in June of 2025.





Cost Of Sales Change Date
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
Almirall EUR 191.5M 2.29M Dec/2025
Amarin USD 16.89M 18.51M Mar/2025
Amgen USD 1.79B 128M Dec/2025
argenx SE USD 149.69M 40.26M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Bayer EUR 4.31B 57M Sep/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Demant DKK 2.89B 188M Dec/2025
Exelixis USD 26.48M 7.91M Dec/2025
Fresenius Medical Care EUR 3.68B 38.37M Dec/2025
Galapagos EUR 84.73M 80.02M Sep/2025
Genmab DKK 57M 15M Jun/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
GN Store Nord DKK 2.24B 338M Dec/2025
GRIFOLS EUR 1.13B 15.63M Sep/2025
Hikma Pharmaceutical USD 466.5M 428.5M Jun/2025
Insmed USD 46.16M 15.25M Dec/2025
Lonza CHF 2.28B 189M Jun/2025
Merck EUR 2.1B 123M Sep/2025
Novartis USD 3.54B 217M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
UCB EUR 901M 50M Dec/2024